Definium Therapeutics News - October 2026

JPMorgan Bets Big on Definium's Brain Drug — But Can a Small Biotech Really Double From Here?

Shares of Definium Therapeutics surged 10.2% to $37.65 on October 9 after JPMorgan initiated coverage with an Overweight rating and an $84 price target —...

🟢 Definium Therapeutics is trading 10% up today after JPMorgan initiated coverage with an Overweight rating

Definium Therapeutics is trading at $37.65 (+10.15%) after JPMorgan initiated coverage with an Overweight rating. - JPMorgan set an $84 price target and...